Affimed Announces Acceptance of AFM24 Clinical Abstract at the 2024 Annual Meeting of the American Society of Clinical Oncology
Affimed (NASDAQ: AFMD) had its "overweight" rating re-affirmed by analysts at Cantor Fitzgerald.
Affimed (NASDAQ: AFMD) had its price target lowered by analysts at Wells Fargo & Company from $30.00 to $25.00. They now have an "overweight" rating on the stock.
Affimed (NASDAQ: AFMD) had its price target raised by analysts at Stifel Nicolaus from $1.00 to $5.00. They now have a "hold" rating on the stock.
Affimed (NASDAQ: AFMD) had its price target raised by analysts at HC Wainwright to $10.00. They now have a "buy" rating on the stock.